VIKING GLOBAL INVESTORS LP 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:31 pm Sale |
2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
VIKING GLOBAL INVESTORS LP | 0 0.000% |
-4,247,914 (Position Closed) |
Filing |
| 2024-01-08 4:15 pm Sale |
2024-01-04 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
VIKING GLOBAL INVESTORS LP | 4,247,914 9.900% |
-540,000 (-11.28%) |
Filing |
| 2024-01-08 4:05 pm Purchase |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
VIKING GLOBAL INVESTORS LP | 4,787,914 11.200% |
850,000 (+21.59%) |
Filing |
| 2022-02-14 5:02 pm Unchanged |
2021-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
VIKING GLOBAL INVESTORS LP | 3,937,914 12.300% |
0 (Unchanged) |
Filing |
| 2021-02-12 7:58 pm Unchanged |
2020-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
VIKING GLOBAL INVESTORS LP | 3,937,914 14.900% |
0 (Unchanged) |
Filing |
| 2020-12-21 5:27 pm Purchase |
2020-12-15 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
VIKING GLOBAL INVESTORS LP | 3,937,914 14.900% |
3,937,914 (New Position) |
Filing |